SCHEMBL29299599

SCHEMBL29299599

CC(C)CCCCNC(=O)CCNC(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
CASP2 P42575 1/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NAAA Q02083 1/20 0.41
NAMPT P43490 2/20 0.40
HPGD P15428 2/20 0.40
CNR1 P21554 1/20 0.40
EPHX1 P07099 2/20 0.40
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29299613 0.95 ALDH1A1 (0.46) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL19239840 0.91 NAMPT (0.45) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL26818740 0.90 CASP2 (0.44) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL23320103 0.90 NAMPT (0.47) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL23320102 0.90 NAMPT (0.47) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL23319056 0.90 NAMPT (0.47) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL26700781 0.90 NAMPT (0.47) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL24934996 0.89 LMNA (0.45) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL15160690 0.87 ALDH1A1 (0.50) ALDH1A1CASP2LMNAPKMKMT2A
SCHEMBL19880188 0.87 CASP2 (0.52) ALDH1A1CASP2KMT2AMEN1NAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226343-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R ALDH1A1 3906/4885CASP2 3823/4885LMNA 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.